Wild type ATTR amyloidosis

This study tests the long-term safety and tolerability of acoramidis, an oral medication that stabilizes the transthyretin protein, in people newly diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that can lead to heart failure. Participants who complete…

This study explores whether specialized eye imaging can identify people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers will use machine learning to analyze eye scans from 500 adults—some with ATTR-CM and others with heart failure bu…

This study tests a special radioactive tracer called [68Ga]Ga-FAPI-46 for PET scans in 40 people with transthyretin cardiac amyloidosis (ATTR-CM), a condition where abnormal proteins build up in the heart. The goal is to see if this scan can measure scar-like activity in the hear…

This study will test whether a faster type of bone scan (CZT-SPECT) can accurately diagnose transthyretin cardiac amyloidosis, a serious heart condition. Researchers will compare the new scan with the standard method in 200 patients. If it works, it could make diagnosis quicker a…

This study tests whether a computer model can find signs of a heart condition called cardiac amyloidosis in bone scans that were done for other reasons. Researchers will look back at 57 patients' scans to see if the model can correctly identify those with the disease. If it works…

This study tests whether a special PET-CT scan using a drug called evuzamitide can detect signs of cardiac amyloidosis in people whose standard heart scans were unclear but who have high levels of a blood marker called TAD1. About 25 adults with heart failure or a genetic risk fo…

This study tests whether a structured 5-week cardiac rehabilitation program can improve exercise ability and quality of life in 40 adults with cardiac amyloidosis. Participants will undergo supervised aerobic and strength training five days a week, with tests before and after the…

This study tests whether increasing the pacemaker's lower rate from 60 to 80 beats per minute improves quality of life and daily function in people with ATTR cardiac amyloidosis. The heart in this condition is stiff and depends on a faster heart rate to pump blood. Thirty-four pa…

This study tests whether a home-based exercise program combined with nutritional supplements can improve walking ability and muscle strength in people aged 70 and older with transthyretin cardiac amyloidosis, a heart condition that causes weakness and frailty. About 102 participa…

This study looks at whether a digital tool called Luscii is practical and acceptable for people with a rare heart condition called ATTR-CM. About 60 adults in Austria, Germany, and Italy will use a smartphone app and home devices to share health information with their care team. …

This observational study monitors the long-term safety of eplontersen, a treatment for transthyretin amyloidosis, in patients who have had a liver transplant or have severe liver impairment. Researchers will track side effects, lab changes, and serious health events in about 320 …

This study will follow 200 people with suspected or confirmed cardiac amyloidosis, a condition where abnormal proteins build up in the heart and cause heart failure. Over two years, participants will undergo heart MRI scans, exercise tests, and blood work at regular visits. The g…

This study will observe 143 older adults with severe aortic stenosis who are scheduled for a minimally invasive valve replacement procedure called TAVR. Researchers want to find out how many also have cardiac amyloidosis, a condition where abnormal proteins build up in the heart.…